KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Consensus Target Price from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are currently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $24.83.

A number of equities analysts have weighed in on KALV shares. Jones Trading restated a "buy" rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, March 14th.

Insiders Place Their Bets

In other news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $9.42 per share, with a total value of $235,500.00. Following the completion of the transaction, the insider now owns 5,303,985 shares of the company's stock, valued at $49,963,538.70. This represents a 0.47% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the transaction, the insider now owns 106,611 shares of the company's stock, valued at approximately $1,262,274.24. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,730 shares of company stock worth $102,226 over the last three months. Company insiders own 10.50% of the company's stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently bought and sold shares of KALV. SG Americas Securities LLC increased its stake in shares of KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock valued at $123,000 after purchasing an additional 1,319 shares in the last quarter. Legal & General Group Plc grew its stake in shares of KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after buying an additional 1,494 shares during the last quarter. Rhumbline Advisers increased its position in KalVista Pharmaceuticals by 3.4% during the 1st quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock valued at $611,000 after buying an additional 1,762 shares in the last quarter. Corebridge Financial Inc. raised its stake in KalVista Pharmaceuticals by 12.7% during the first quarter. Corebridge Financial Inc. now owns 19,094 shares of the specialty pharmaceutical company's stock valued at $220,000 after buying an additional 2,149 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in KalVista Pharmaceuticals by 13.2% in the first quarter. MetLife Investment Management LLC now owns 21,688 shares of the specialty pharmaceutical company's stock worth $250,000 after acquiring an additional 2,536 shares in the last quarter.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV traded up $0.56 during trading hours on Thursday, hitting $14.36. The company had a trading volume of 544,195 shares, compared to its average volume of 433,407. The firm has a 50 day simple moving average of $12.01 and a 200 day simple moving average of $10.57. The firm has a market capitalization of $713.92 million, a price-to-earnings ratio of -3.95 and a beta of 0.05. KalVista Pharmaceuticals has a 52 week low of $7.30 and a 52 week high of $15.50.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).